studypressure

152 results found.

Top Stocks matching your search for "study pressure"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 15, 2023

$SAVA “Treatment also eased depression and dementi... See more

Feb, 6, 2023

Simufilam reduced dementia-related behavior at 9 m... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
HEPA

Hepion Pharmaceuticals Inc

-16.85%

$0.86 - $0.72

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 18, 2023

Anyway, since this trial is expensive and yet nece... See more

Jan, 11, 2023

2023 is going to be highlighted with a continuous ... See more

02/1002/1502/2102/2403/0103/0603/0903/1403/1703/22
RSLS

ReShape Lifesciences Inc.

-48.86%

$5.91 - $3.02

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Feb, 16, 2023

$RSLS Nice consolidation phase before this one goes.

Feb, 8, 2023

$RSLS nice green boom boom after closed offering ... See more

SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 15, 2023

$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”

Feb, 6, 2023

Simufilam reduced dementia-related behavior at 9 months on the Neuropsychiatric Inventory (NPI), a clinical tool widely used to measure changes in dementia-related behavior.

Feb, 1, 2023

The open label study is a true gift which gives us insight on both health and benefit issues and the med looks great on both counts.

Jan, 17, 2023

$SAVA September 3rd 2021 Remi Barbier said, "I truly believe Cassava Sciences is one clinical program away from greatness.

Jan, 6, 2023

$SAVA Per press release dec 6 2022, Remi stated administration of drug for OL study completed and he is "THRILLED" with the clinical development, or what he see to this date.

Jan, 4, 2023

$SAVA , VERA announced positive phase 2b results meeting primary end point.

Dec, 27, 2022

My prediction: Phase 2 Unbelievable results FDA fast track Phase 3 - go ahead Patients receive sava Market cap 40 B by 2024 Rising to 200 Billion by 2026 Game changer - the only drug in the world to help patients

HEPA

Hepion Pharmaceuticals Inc

-16.85%

$0.86 - $0.72

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 18, 2023

Anyway, since this trial is expensive and yet necessary for regulatory approval; I interpret it as a bullish signal.

Jan, 11, 2023

2023 is going to be highlighted with a continuous cascade of amazingly positive PR’s confirming the fact (already documented in 300+ early clinical studies), that Rencofilstat is truly a Wonder Drug to be celebrated, with an extraordinarily large TAM.

Jan, 11, 2023

$HEPA Was hoping we would get an update on our (Nash) trial soon and we got this surprising good news.

Jan, 9, 2023

I didnt sell a share and with stellar results for this soon to be released study it should gain traction well over 3 imo.

Dec, 28, 2022

We knows recession is coming next year 4) XBI has bottomed and should begin its upward move next year 5) Phase 2b trial results and updates on HCC trial 6) Probable approvals of NASH drugs and increased bullish sentiment in the sector

Dec, 20, 2022

Sign up for the free trial, it's easy.

Dec, 19, 2022

button for good trial results in the NASH space.

Dec, 19, 2022

Highly statistically significant results because of the large trial size.

RSLS

ReShape Lifesciences Inc.

-48.86%

$5.91 - $3.02

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Feb, 16, 2023

$RSLS Nice consolidation phase before this one goes.

Feb, 8, 2023

$RSLS nice green boom boom after closed offering $FWBI new clinical study news $KPRX $CELZ $ICU

Jan, 3, 2023

$PBLA multiple phase 3 trail ..price 8 cents ..dirt cheap $KALA $RSLS $ATNF $PTPI